Journal of Diabetes and Metabolic Disorders最新文献

{"title":"DPP-IV and FAS inhibitory peptides: therapeutic alternative against diabesity.","authors":"Ma Fabiola León-Galván, Daniela Sarahi Medina-Rojas","doi":"10.1007/s40200-025-01613-9","DOIUrl":"10.1007/s40200-025-01613-9","url":null,"abstract":"<p><p>Diabesity is a modern epidemic that indicates a strong association between obesity and diabetes. Key enzymes have been identified in the development and progression of both diseases, DPP-IV in glucose uptake and FAS in fatty acid synthesis. In both cases, the molecular mechanisms of how each one acts separately have been described, and which are the key inhibitory drugs and molecules for each one. However, although it is known that there is an association between both clinically and molecularly, the mechanism has not been elucidated; therefore, this review focuses on proposing a mechanism of convergence of DPP-IV and FAS in diabesity, and the possible mode of action in which bioactive peptides obtained from plant and animal sources can inhibit these two enzymes in a similar way as drugs do.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"100"},"PeriodicalIF":1.8,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Body Shape Index (ABSI) as a risk factor for all-cause mortality among US adults with type 2 diabetes: evidence from the NHANES 1999-2018.","authors":"Feng Chen, Xi Xie, Sijia Xia, Weilin Liu, Jingfang Zhu, Qing Xiang, Rui Li, Wenju Wang, Tao Jiang, Mengquan Tan","doi":"10.1007/s40200-025-01570-3","DOIUrl":"10.1007/s40200-025-01570-3","url":null,"abstract":"<p><strong>Background and objective: </strong>A Body Shape Index (ABSI) serves as a potential indicator of fat distribution, offering a more reliable association with all-cause mortality compared to overall adiposity. The present cohort study aims to explore the relationship between ABSI and all-cause mortality in US adults with Type 2 Diabetes (T2D).</p><p><strong>Methods: </strong>For this cohort study, we extracted information on 5,461 US adults with T2D from the National Health and Nutrition Examination Survey (NHANES) and the NHANES Linked Mortality File. Trends in ABSI from 1999 to 2018 were calculated and analyzed using partial Mann-Kendall tests. To assess the relationship between ABSI and all-cause mortality, as well as the robustness of the association results, we employed weighted restricted cubic splines (RCS), weighted Cox proportional hazards models, sensitivity analyses, and stratified analyses. Additionally, we conducted time-dependent receiver operating characteristic (ROC) curve analysis to evaluate ABSI's predictive capability for all-cause mortality over 3, 5, and 10 years.</p><p><strong>Results: </strong>Among US adults with Type 2 Diabetes (T2D), the mean ABSI gradually increased from 0.08333 to 0.08444 between 1999 and 2018. Following a median follow-up period of 90 months, 1,355 deaths (24.8% of the participants) occurred due to all causes. A left J-shaped association was observed between ABSI and all-cause mortality, with a 39% increased risk among US adults with T2D who had an ABSI below 0.08105 after full adjustment.</p><p><strong>Conclusion: </strong>Our research has demonstrated a significant association between an elevated ABSI and the risk of all-cause mortality among US adults with T2D. These findings support the potential use of ABSI as a noninvasive tool to estimate mortality risk among US adults with T2D.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01570-3.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"99"},"PeriodicalIF":1.8,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the bidirectional association between thyrotropin and thyroid hormones in type 2 diabetes: a systematic review and meta-analysis.","authors":"Alireza Amirabadizadeh, Alireza Ghorbani, Fereidoun Azizi, Hengameh Abdi, Atieh Amouzegar, Ladan Mehran","doi":"10.1007/s40200-025-01612-w","DOIUrl":"10.1007/s40200-025-01612-w","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) and thyroid dysfunction are some of the most prevalent endocrine disorders globally. Previous studies on the association and effect of thyroid hormones in patients with diabetes have yielded contradictory results. Therefore, this meta-analysis comprehensively examined the latest evidence regarding the bilateral association between thyrotropin and thyroid hormone levels in T2DM.</p><p><strong>Methods: </strong>A thorough search across multiple databases was conducted to investigate the bidirectional relationship between thyroid hormones and T2DM. Two researchers independently performed data extraction and study quality was assessed using the Newcastle-Ottawa scale, with prevalence, odds ratios, and hazard ratios calculated using a random-effects model.</p><p><strong>Results: </strong>After screening 4159 studies, 36 were deemed eligible based on the inclusion criteria. A one-unit increase in serum thyroid-stimulating hormone (TSH) level was associated with a 2.49-fold increased odds of T2DM (OR: 2.49, 95%CI: 1.97-3.0). Similarly, a one-unit increase in Triiodothyronine (FT3) levels was associated with a 17% (HR:1.17,95%CI: 1.07-1.26) increased risk of T2DM. The pooled risk estimates of T2DM were 3.63 (95%CI: 1.63-8.09) for hypothyroidism, and 16.33 (95%CI: 7.59-35.12) for overt hypothyroidism. Individuals with thyroid dysfunction exhibited significantly higher HbA1c levels (Hedges'g: - 0.26, 95% CI: - 0.47 to - 0.06) and fasting plasma glucose (FPG) levels (Hedges'g: - 0.33, 95% CI: - 0.61 to - 0.05) compared to those with normal thyroid function.</p><p><strong>Conclusions: </strong>Thyroid dysfunction, including both overt and subclinical hypo- and hyperthyroidism, significantly increases the risk of T2DM. Elevated TSH and FT3 levels are linked to higher diabetes risk, highlighting the need for regular thyroid screening and integrated clinical management.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01612-w.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"98"},"PeriodicalIF":1.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of postprandial C peptide in obese patients with prediabetes and type 2 diabetes before and after sleeve gastrectomy.","authors":"Shrook Mousa, Aasem Saif, Hisham Aboueisha, Doaa M A Mostafa, Noha M T El-Dessouky, Shereen El-Sawy","doi":"10.1007/s40200-025-01599-4","DOIUrl":"10.1007/s40200-025-01599-4","url":null,"abstract":"<p><p>Obesity is a complicated, multifactorial, and highly avoidable disease. There is a complicated relationship between type 2 diabetes mellitus (T2DM) and obesity. Surgical intervention is regarded as one of the greatest efficacious treatments for morbid obesity, where T2DM exhibits remarkable amelioration and remission. The objective of this work is to evaluate endogenous insulin by measuring postprandial C-peptide before and 6 months after LSG. We will also assess metabolic improvement, including remission of T2DM and prediabetes, 6 months after LSG. A total of 60 Egyptian patients, aged 18-60 years, with a body mass index (BMI) > 35, prediabetes, or type 2 diabetes, were recruited from bariatric outpatient clinics at Cairo University Hospitals. The study assessed the postprandial C-peptide, fasting blood sugar, HbA1C, and lipid profile before and 6 months following LSG. A significant improvement was observed in the metabolic profile in the form of reduction of BMI, HbA1c, lipid profile, and control of hypertension 6 months postoperatively. There was a significant reduction of postprandial C-peptide 6 months postoperatively. Fifty-five patients (91.7%) achieved complete remission of prediabetes and diabetes 6 months postoperatively, while 4 patients showed only improvement of diabetes and 1 patient in the prediabetic group did not achieve remission. In conclusion, LSG demonstrates encouraging outcomes in terms of metabolic profile enhancement, insulin resistance improvement as indicated by significant reduction in C-peptide level, remission of prediabetes and T2DM, and effective weight loss.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"97"},"PeriodicalIF":1.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of submaximal and maximal training on serum levels of asprosin, metabolic parameters and body composition in overweight and obese women.","authors":"Atefeh Sadeghi, Parvaneh Nazarali, Rostam Alizadeh, Halil İbrahim Ceylan, Hadi Nobari","doi":"10.1007/s40200-025-01608-6","DOIUrl":"10.1007/s40200-025-01608-6","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the effects of maximal and submaximal exercise training on serum levels of Asprosin, insulin resistance, and body composition in overweight and obese women.</p><p><strong>Methods: </strong>30 overweight/obese women voluntarily participated in the study and were then randomly divided into control, submaximal, and maximal groups. A treadmill high-intensity exercise protocol was applied to MG non-consecutive three days a week for 8 weeks, in four 4-min intervals with an intensity of 70 to 95% of maximum heart rate (HRmax) with 3-min active recovery intervals. SMG performed a moderate-intensity exercise protocol of approximately 25 to 35 min at the treadmill at 50-70% of HRmax non-consecutive days three days per week for 8 weeks. The CG continued their daily routine activities. Anthropometric and body composition measurements such as body weight, height, BMI, and waist-hip ratio (WHR) were performed before and after the 8-week training period. Fasting blood glucose (FGB), insulin, insulin resistance (HOMA-IR), and serum asprosin levels were also measured.</p><p><strong>Results: </strong>Post-training, there were significant main effects of time and a group-by-time interaction for all body composition and performance variables (<i>p</i> < 0.001). Post hoc analysis revealed that body mass, BMI, WHR, FBG, insulin, HOMA-IR, and serum asprosin were significantly reduced after 8 8-week training program.</p><p><strong>Conclusions: </strong>The present study showed that maximal and submaximal exercise protocols effectively improved body composition, insulin sensitivity, resistance, and reduced asprosin level. It has been concluded that these effects are more pronounced, especially after maximal exercise protocols.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"96"},"PeriodicalIF":1.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal obesity as a risk factor for sarcopenia among the community-dwelling older adults: data from baseline phase of Birjand longitudinal aging study.","authors":"Niusha Amirani, Kian Goudarzi, Zohreh Sajadi Hezaveh, Mitra Moodi, Hossein Fakhrzadeh, Masoumeh Khorashadizadeh, Huriye Khodabakhshi, Shohreh Naderimagham, Akam Ramezani, Hanieh-Sadat Ejtahed, Farshad Sharifi","doi":"10.1007/s40200-025-01616-6","DOIUrl":"10.1007/s40200-025-01616-6","url":null,"abstract":"<p><strong>Objectives: </strong>Sarcopenia could be linked to abdominal obesity through various mechanisms. The aim of the current study was to evaluate the association between sarcopenia and abdominal obesity among community-dwelling aged population.</p><p><strong>Methods: </strong>Data were collected from 1356 eligible older adults (≥ 60 years) who participated in the baseline phase of Birjand Longitudinal Aging Study (BLAS) in 2019. Body mass index (BMI), waist circumference (WC), hip circumference (HC), waist-to-height ratio (WHtR), waist-to-hip ratio (WHR), a body shape index (ABSI), body roundness index (BRI), and body adiposity index (BAI) were measured. Sarcopenia was assessed based on hand grip strength, appendicular skeletal muscle mass (ASMM) and gait speed.</p><p><strong>Results: </strong>In the studied population, 834 individuals were sarcopenic. The best predictors of sarcopenia and low gait speed were BAI and WHtR (AUC = 0.61 to 0.65). All abdominal obesity indices were risk factors for sarcopenia, except for WHR. ABSI was significantly and directly associated with sarcopenia, only in the crude model (OR (95%CI): 1.14 (1.02; 1.28), <i>P</i> = 0.02). WHR, WHtR, BMI, and WC increased and ABSI decreased the odds of low handgrip strength.</p><p><strong>Conclusions: </strong>Most abdominal obesity indices were identified as risk factors for sarcopenia except for WHR. Anthropometric indices can be considered for evaluating the risk of sarcopenia in the elderly.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01616-6.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"95"},"PeriodicalIF":1.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between duration of metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis.","authors":"Mansour Bahardoust, Yadollah Mehrabi, Farzad Hadaegh, Fereidoun Azizi, Davood Khalili, Ali Delpisheh","doi":"10.1007/s40200-025-01577-w","DOIUrl":"10.1007/s40200-025-01577-w","url":null,"abstract":"<p><strong>Objectives: </strong>The effect of the duration of medication with metformin and sulfonylurea (SUs) on microvascular complications based on the duration of type 2 diabetes (DM2) is unclear. The aim of this study was to investigate the association of medication time with metformin and SUs and microvascular complications in newly diagnosed DM2 patients.</p><p><strong>Methods: </strong>In this prospective multi-cohort study, data from 3,904 newly diagnosed DM from three cohorts of the Tehran Lipid and Glucose Study (TLGS), the Multi-Ethnic Study of Atherosclerosis (MESA), and the Atherosclerosis Risk in Communities (ARIC) with a mean age of 59.6 ± 08 years were pooled. Metformin medication time alone, SUs alone, and a combination of both since drug initiation were defined as exposure. The incidence of microvascular complications (diabetic nephropathy or retinopathy) was defined as outcomes. The cumulative exposure to metformin, SUs, aspirin, statin, and anti-hypertensive medication was also determined using the same approach.</p><p><strong>Results: </strong>Metformin alone, SUs alone, and the combination of both reduced the hazard of microvascular complications by 8%(HR_Adj: 0.92, 95% CI: 0.89, 0.96, P: 0.001), 6%(HR_Adj: 0.94, 95% CI: 0.92, 0.97, P: 0.004), and 9%(HR_Adj: 0.91, 95% CI: 0.89, 0.94, P: 0.001) for each year of use, respectively (<i>p</i> < 0.05). The protective effect of metformin and SUs, individually or in combination, on microvascular complications started approximately five years after the initial treatment and continued until approximately 15 years after the initial treatment and then reached a plato.</p><p><strong>Conclusion: </strong>long-term use of metformin and SUs individually and in combination was associated with a decrease in the risk of microvascular outcomes in newly diagnosed DM for up to about one decade. These findings highlight the importance of choosing an appropriate treatment regimen for new patients with type 2 diabetes. Appropriate oral therapy can minimize microvascular complications and improve overall well-being.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01577-w.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"94"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review.","authors":"Mahshad Gholami, Narges Zargar Balajam, Samira Rakhsha, Sayed Mahmoud Sajjadi-Jazi, Gita Shafiee, Ramin Heshmat","doi":"10.1007/s40200-025-01604-w","DOIUrl":"10.1007/s40200-025-01604-w","url":null,"abstract":"<p><strong>Objectives: </strong>Diabetes mellitus (DM) is often accompanied by various comorbidities, including cardiovascular diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), renal dysfunction, polycystic ovary syndrome (PCOS), neurological disorders, psychiatric conditions, and others. These comorbidities complicate diabetes management and contribute to worsened health outcomes. This narrative review explores the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in managing a broad range of diabetes-related comorbidities, assessing their therapeutic potential beyond glycemic control.</p><p><strong>Methods: </strong>A comprehensive review of the literature was conducted by searching scientific databases including PubMed, Scopus, and Web of Science. Additionally, AI-based tools like ChatGPT were employed from <b>September 2024 to January 2025</b> to enhance the accuracy of data collection and analysis. The search was conducted using keywords such as \"GLP-1 receptor agonists\", \"diabetes and comorbidities\", \"cardiovascular diseases\", \"MASLD\", \"renal dysfunction\", \"PCOS\", \"neurological disorders\", \"psychiatric disorders\", \"sleep apnea\", \"osteoarthritis\", and \"diabetic retinopathy\". Boolean operators (AND/OR) were used to combine the keywords for efficient searching. Studies were selected and analyzed based on predefined criteria to evaluate the efficacy of GLP-1 receptor agonists (GLP1RAs) in managing diabetes-related comorbidities.</p><p><strong>Results: </strong>GLP1RAs have demonstrated significant benefits in managing various comorbidities, including cardiovascular diseases, liver conditions (such as MASLD), renal dysfunction, and metabolic disorders like PCOS. They also show promise in addressing neurological and psychiatric disorders, likely due to their anti-inflammatory, neuroprotective, and metabolic effects.</p><p><strong>Conclusion: </strong>GLP1RAs offer a multifaceted approach to treating not only diabetes but also its associated comorbidities, improving patient outcomes across multiple health domains. However, further research is required to confirm these benefits and optimize treatment strategies for diverse patient populations.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01604-w.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"92"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linc-PINT downregulation of TGF-β signaling pathway in heart arrhythmia: an in silico analysis.","authors":"Arash Amin, Mahya Bakhshi Ardakani, Maryam Saadatakhtar, Aida Zeinali, Shana Ahadi, Azadeh Fateh, Zohreh Salehnassaj, Fatemeh Dadgar, Farnaz Khodaparast","doi":"10.1007/s40200-025-01609-5","DOIUrl":"10.1007/s40200-025-01609-5","url":null,"abstract":"<p><p>Heart Arrhythmias (HA) is one of the heart diseases that occurs due to heart dysfunction or contraction of myocardial cells. Long non-coding RNAs (LncRNAs) are one of the factors that play a role in the physiopathology of HA. TGF-β plays a pivotal role in the pathogenesis of HA. Recently, it has been shown that linc-PINT can play a role in regulating TGF-β expression. However, the interaction of these two molecules in HA has not been investigated in silico, so we evaluated this issue in this study. We accessed the GSE133420 (platform: GPL20795 HiSeq X Ten (Homo sapiens)) dataset containing RNA-seq data from human atrial appendage tissues from patients with atrial fibrillation (AF) and healthy controls. It deals with RNA isolates obtained from plasma samples. To identify potential binding sites for linc-PINT within the promoters of TGF-β signaling genes, we used LncRRIsearch. To further validate and supplement these predictions, we also referenced target genes from LncTar and starBase, which were then integrated into the protein-protein interaction (PPI) network. The results showed that the expression of linc-PINT was significantly decreased in patients compared to the control group (<i>p</i> < 0.01). On the other hand, the expression of SMAD2, SMAD3, SMAD5 and TGF-βR1 genes was significantly increased in patients compared to the control group. The expression of SMAD6 in both groups was almost equal and there was no significant relationship between them (<i>P</i> > 0.05). It can be said that examining the expression of TGF-β and linc-PINT can be helpful in identifying patients at high risk of HA, and by applying therapeutic strategies, clinical symptoms can be improved.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01609-5.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"93"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bariatric surgery in Poland in 2017-2022: retrospective analysis of public health system open data.","authors":"Mikołaj Kamiński, Mariusz Wyleżoł, Matylda Kręgielska-Narożna, Paweł Bogdański","doi":"10.1007/s40200-025-01600-0","DOIUrl":"10.1007/s40200-025-01600-0","url":null,"abstract":"<p><strong>Background: </strong>There little known about bariatric surgeries performed in Poland. We aimed to analyze trends in bariatric surgery performed in public health system in Poland.</p><p><strong>Methods: </strong>Data was obtained from the National Health Fund (NFZ) database of aggregated statistics for the years 2017-2022. We retrieved data about hospitalizations during which bariatric surgery was performed. We performed descriptive statistics.</p><p><strong>Results: </strong>From 2017 to 2022, the number of bariatric surgeries in Poland's public healthcare system increased from 3,278 to 5,580, with a temporary decline in 2020. The number of procedures per 100,000 residents increased from 8.5 in 2017 to 14.7 in 2022. The majority of surgeries (73.3%) were performed on women. Sleeve gastrectomy was the most frequently reported procedure. The median duration of hospitalizations was 3 days. The in-hospital mortality rate was equal to 0.057.</p><p><strong>Conclusions: </strong>Between 2017 and 2022, bariatric surgeries in the Polish public healthcare system increased by about 70%, with a temporary drop in 2020. Nevertheless, Poland still reports fewer procedures per 100,000 residents compared to other developed countries. A key limitation of this study is the absence of data from private sector.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01600-0.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"91"},"PeriodicalIF":1.8,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}